Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin

AstraZeneca

Status and phase

Terminated

Phase 2

Conditions

Diabetes Mellitus

Treatments

Drug: placebo

Drug: exenatide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00701935

H8O-CA-GWCE

Details and patient eligibility

About

A multicenter, randomized, double-blind, placebo-controlled trial will assess the effects of twice-daily subcutaneous injection with exenatide versus treatment with matching placebo injection on abdominal visceral fat content.

Enrollment

80 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients between 18 and 85 years of age, inclusive.
Patients with type 2 diabetes
Patients have been treated with metformin, at a stable dose for at least 3 months prior to Visit 1
Patients have HbA1c of 7.0% to 8.9%, inclusive.
Patients have a body mass index >27 kg/m2 and <40 kg/m2 and meet local CT scan body weight requirements. For South Asian, Japanese, and Chinese patients, a body mass index >=25 kg/m2 is acceptable as the lower limit.
Patients have a history of stable body weight (not varying by >2 kg in the 3 months prior to Visit 1).
Medications for the treatment of high blood pressure are stable with respect to treatment regimen for 4 weeks prior to Visit 1.
Stable regimen of lipid-lowering agents for 6 weeks prior to Visit 1.

Exclusion criteria

Have received treatment in the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
Have a history of renal transplantation, or are currently receiving renal dialysis.
Have had a clinically significant history of cardiac disease or presence of active cardiac disease within 1 year prior to Visit 1, including myocardial infarction, clinically significant arrhythmia, unstable angina, moderate to severe congestive heart failure, coronary artery bypass surgery, or angioplasty; or is expected to require coronary artery bypass surgery or angioplasty during the course of the study.
Have known hemoglobinopathy or clinically significant, chronic anemia.
Known or are likely to become transfusion dependent during the study.
Have active, symptomatic proliferative retinopathy.
Are receiving chronic treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility. (i.e. metoclopramide, cisapride, and chronic use of macrolide antibiotics)
Have severe gastrointestinal disease, including gastroparesis.
Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 months immediately prior to Visit 1.
Have taken exenatide, liraglutide or any other GLP-1 receptor agonist in the past 6 months, either in a clinical study or as commercially available medication. Patients with known allergy to exenatide should be excluded.
Have used any prescription or over the counter drug to promote weight loss within 3 months prior to Visit 1, or intend to use such a drug during the study. (Examples: Xenical [orlistat], Meridia [sibutramine], Acutrim [phenylpropanolamine], Acomplia [rimonabant]).
Have participated in a structured weight loss program within 3 months prior to Visit 1, or intend to participate in such a plan during this study.
Have been treated for longer than 2 weeks with any of the following excluded medications within 3 months prior to Visit 1: Insulin; Thiazolidinediones; Alpha-glucosidase inhibitors; Sulfonylureas; Oral DPP-IV inhibitors; Meglitinides.
Are taking warfarin, or a coumarol derivative.